Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors

Drug and Alcohol Review

Volumn 35, Issue 3, 2016, Pages 326-333

  Lucas, Philippe ^a   Walsh, Zach ^b   Crosby, Kim ^b   Callaway, Robert ^c   Belle Isle, Lynne ^a,d   Kay, Robert ^e   Capler, Rielle ^f   Holtzman, Susan ^b  

^a UNIVERSITY OF VICTORIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Canadian AIDS Society ^*  (Canada)

^d CANADIAN AIDS SOCIETY   (Canada)

^e GreenLeaf Technologies   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Addiction; Cannabis; Marijuana; Substance use; Substitution effect

Indexed keywords

MEDICAL CANNABIS; STREET DRUG;

ADOLESCENT; ADULT; AGE; CANADA; CANNABIS SMOKING; CROSS-SECTIONAL STUDY; DRINKING BEHAVIOR; DRUG DEPENDENCE; FEMALE; HARM REDUCTION; HUMAN; MALE; MIDDLE AGED; QUESTIONNAIRE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ALCOHOL DRINKING; CANADA; CROSS-SECTIONAL STUDIES; FEMALE; HARM REDUCTION; HUMANS; MALE; MARIJUANA SMOKING; MEDICAL MARIJUANA; MIDDLE AGED; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84941585246     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12323     Document Type: Article

References (39)

1. Russo EB. History of cannabis and its preparations in sage, science, and sobriquet. Chem Biodivers 2007;4:1614-1648.
2. Fankhauser M. History of cannabis in Western medicine. In: Russo FGE, ed. Cannabis and cannabinoids. New York: Haywared Integrative Press, 2002.
3. Grinspoon L, Bakalar JB. Marijuana the forbidden medicine. New Haven, CT: Yale University Press, 1993.
4. Boyd S. From witches to crack moms. Durham, North Carolina: Carolina Academic Press, 2004.
5. Solomon R, Murphy E. The black candle. Toronto, ON: Coles Publishing Company, 1973.
6. Lucas P, Reiman A, Earleywine M, etal. Cannabis as a substitute for alcohol and other drugs: a dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addict Res Theory 2013;21:435-442.
7. Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 2010;5(Special Issue):1-21.
8. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1-25.
9. Grotenhermen FRE. Cannabis and cannabinoids. New York: Haworth Press, 2002.
10. Bewley-Taylor D, Blickman T, Jelsma M The rise and decline of cannabis prohibition. 2014. Available at: http://www.tni.org/rise-and-decline (accessed 16 August 2015).
11. Hursh SR, Galuska CM, Winger G, Woods JH. The economics of drug abuse: a quantitative assessment of drug demand. Mol Interv 2005;5:20-28.
12. Model KE. The effect of marijuana decriminalization on hospital emergency drug episodes: 1975-1978. J Am Stat Assoc 1993;88:737-747.
13. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002209.
14. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271:1940-1947.
15. Allsop DJ, Dunlop J, Saddler C, Rivas GR, McGregor IS, Copeland J. Changes in cigarette and alcohol use during cannabis abstinence. Drug Alcohol Depend 2014;138:54-60.
16. Aharonovich E, Garawi F, Bisaga A, Brooks D, Raby WN, Rubin E Australian Institute of Health and Welfare 2001 National Drug Strategy Household Survey: First results. Canberra (Australia) Australian Institute of Health and Welfare; 2002. Report No.: PHE35.
17. Aharonovich E, Garawi F, Bisaga A, etal. Concurrent cannabis use during treatment of comorbid ADHD and cocaine dependence: effects and outcome. Am J Drug Alcohol Abuse 2006;32:629-635.
18. Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J 2009;6:35.
19. Scavone JL, Sterling RC, Weinstein SP, Van Bockstaele EJ. Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict 2013;22:344-351.
20. Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain, and implications for problematic substance use, public health, and drug policy. J Psychoactive Drugs 2012;44:125-133.
21. Ramesh D, Owens R, Kinsey S, Cravatt B, Sim-Selley L, Lichtman A Effects of chronic manipulation of the endocannabinoid system on precipitated opioid withdrawal. Poster presented at: The 21st Annual International Cannabinoid Research Society Symposium on the Cannabinoids; 2011; St. Charles, IL.
22. Swartz R. Medical marijuana users in substance abuse treatment. Harm Reduct J 2010;7:3.
23. Peters EN, Hughes JR. Daily marijuana users with past alcohol problems increase alcohol consumption during marijuana abstinence. Drug Alcohol Depend 2010;106:111-118.
24. Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs 2011;43:128-135.
25. Belle-Isle L, Walsh Z, Callaway R, etal. Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy 2014;25:691-699.
26. Lucas PG. Regulating compassion: an overview of Canada's federal medical cannabis policy and practice. Harm Reduct J 2008;5:5.
27. Lucas P. Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice. Int J Drug Policy 2009;20:296-303.
28. Belle-Isle L, Hathaway A. Barrier to access to medical cannabis for Canadians living with HIV/AIDS. AIDS Care 2007;19:500-506.
29. Health Canada. Marijuana medical access program statistics [Internet]. 2012. Available at: http://www.hc-sc.gc.ca/dhp-mps/marihuana/stat/index-eng.php#a1 (accessed 16 August 2015).
30. Adlaf EM, Begin P, Sawka E Canadian Addiction Survey (CAS): A national survey of Canadian's use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa: Canadian Centre on Substance Use, 2005.
31. Lucas P. It can't hurt to ask; a patient-centered quality of service assessment of Health Canada's medical cannabis policy and program. Harm Reduct J 2012;9:2-11.
32. Walsh Z, Callaway R, Belle-Isle L, Capler R, Kay R, Lucas P. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy 2013;24:511-516.
33. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid overdose mortality in the United States, 1999-2010. JAMA Intern Med 2014;174:1668-1673.
34. Dhalla I, Mamdani M, Sivilotti M, Kopp A, Quershi O, Jurrlink, DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181:891-896.
35. Fischer B, Rehm J, Goldman B, Popova S. Nonmedical use of prescription opioids and public health in Canada: an urgent call for research and intervention development. Can J Public Health 2008;99:182-184.
36. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-1759.
37. Mikuriya T. Cannabis as a substitute for alcohol: a harm reduction approach. J Cannabis Therapeutics 2004;4:79-93.
38. Morris RG, TenEyck M, Barnes JC, Kovandzik TV. The effect of medical marijuana laws on crime: evidence from state panel data, 1990-2006. PLoS ONE 2014;9:e92816.
39. Eysenbach G. Improving the quality of web surveys: the checklist for reporting the results of Internet e-surveys. JMIR 2004;3(e34).